ImmVira wraps up first dosing for MVR-T3011 in US and China
ImmVira said that it has wrapped up the first dosing of its oncolytic virus product – MVR-T3011 intratumoral injection in phase 2 clinical trials both in China and the US. According to the Chinese pharma company, the US phase 2a portion of the study has two parts, of which the first is the evaluation of […]